Northern Trust’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Northern Trust’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-317,526	Closed	-$34.1M	–	4621
2023 Q1	$34.1M	Buy	317,526 +9,486	+3%	+$1.09M	0.01%	1200
2022 Q4	$33.9M	Buy	308,040 +46,438	+18%	+$3.01M	0.01%	1180
2022 Q3	$15.4M	Buy	261,602 +37,440	+17%	+$1.71M	﹤0.01%	1678
2022 Q2	$6.33M	Sell	224,162 -2,443	-1%	-$70.8K	﹤0.01%	2349
2022 Q1	$8.56M	Sell	226,605 -3,595	-2%	-$142K	﹤0.01%	2243
2021 Q4	$9.1M	Buy	230,200 +129,174	+128%	+$4.04M	﹤0.01%	2298
2021 Q3	$2.4M	Sell	101,026 -9,712	-9%	-$229K	﹤0.01%	3191
2021 Q2	$2.72M	Buy	+110,738	New	+$2.47M	﹤0.01%	3207

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Northern Trust's RXDX Position: Q2 2023 in Review

Northern Trust sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 317,526 shares — an estimated $34.1M sold.

Northern Trust first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $34.1M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Northern Trust reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Northern Trust sold 317,526 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $34.1M.
Northern Trust first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Northern Trust's Prometheus Biosciences, Inc. Common Stock position peaked at $34.1M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.